Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer: 18f-fluoroestradiol pet imaging shows return of er expression

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff, Hannah M. Linden

Research output: Contribution to journalArticle

  • 3 Citations

Abstract

Changes in estrogen receptor (ER) expression over the course of therapy may affect response to endocrine therapy. However, measuring temporal changes in ER expression requires serial biopsies, which are impractical and poorly tolerated by most patients. Functional ER imaging using 18F-fluoroestradiol (FES)-PET provides a noninvasive measure of regional ER expression and is ideally suited to serial studies. Additionally, lack of measurable FES uptake in metastatic sites of disease predict tumor progression in patients with ER-positive primary tumors treated with endocrine therapy. This report presents a case of restored sensitivity to endocrine therapy in a patient with bone-dominant breast cancer who underwent serial observational FES-PET imaging over the course of several treatments at our center, demonstrating the temporal heterogeneity of regional ER expression. Although loss and restoration of endocrine sensitivity in patients who have undergone prior hormonal and cytotoxic treatments has been reported, this is, to our knowledge, the first time the accompanying changes in ER expression have been documented by molecular imaging.

LanguageEnglish (US)
Pages144-147
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number2
StatePublished - Feb 1 2016

Fingerprint

Pets
Estrogen Receptors
Breast Neoplasms
Bone and Bones
Therapeutics
Molecular Imaging
Neoplasms
Biopsy

ASJC Scopus subject areas

  • Oncology

Cite this

Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer : 18f-fluoroestradiol pet imaging shows return of er expression. / Currin, Erin; Peterson, Lanell M.; Schubert, Erin K.; Link, Jeanne M.; Krohn, Kenneth A.; Livingston, Robert B.; Mankoff, David A.; Linden, Hannah M.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 2, 01.02.2016, p. 144-147.

Research output: Contribution to journalArticle

@article{e5a5b85718104573b2c485e82ddd470d,
title = "Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer: 18f-fluoroestradiol pet imaging shows return of er expression",
abstract = "Changes in estrogen receptor (ER) expression over the course of therapy may affect response to endocrine therapy. However, measuring temporal changes in ER expression requires serial biopsies, which are impractical and poorly tolerated by most patients. Functional ER imaging using 18F-fluoroestradiol (FES)-PET provides a noninvasive measure of regional ER expression and is ideally suited to serial studies. Additionally, lack of measurable FES uptake in metastatic sites of disease predict tumor progression in patients with ER-positive primary tumors treated with endocrine therapy. This report presents a case of restored sensitivity to endocrine therapy in a patient with bone-dominant breast cancer who underwent serial observational FES-PET imaging over the course of several treatments at our center, demonstrating the temporal heterogeneity of regional ER expression. Although loss and restoration of endocrine sensitivity in patients who have undergone prior hormonal and cytotoxic treatments has been reported, this is, to our knowledge, the first time the accompanying changes in ER expression have been documented by molecular imaging.",
author = "Erin Currin and Peterson, {Lanell M.} and Schubert, {Erin K.} and Link, {Jeanne M.} and Krohn, {Kenneth A.} and Livingston, {Robert B.} and Mankoff, {David A.} and Linden, {Hannah M.}",
year = "2016",
month = "2",
day = "1",
language = "English (US)",
volume = "14",
pages = "144--147",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer

T2 - JNCCN Journal of the National Comprehensive Cancer Network

AU - Currin,Erin

AU - Peterson,Lanell M.

AU - Schubert,Erin K.

AU - Link,Jeanne M.

AU - Krohn,Kenneth A.

AU - Livingston,Robert B.

AU - Mankoff,David A.

AU - Linden,Hannah M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Changes in estrogen receptor (ER) expression over the course of therapy may affect response to endocrine therapy. However, measuring temporal changes in ER expression requires serial biopsies, which are impractical and poorly tolerated by most patients. Functional ER imaging using 18F-fluoroestradiol (FES)-PET provides a noninvasive measure of regional ER expression and is ideally suited to serial studies. Additionally, lack of measurable FES uptake in metastatic sites of disease predict tumor progression in patients with ER-positive primary tumors treated with endocrine therapy. This report presents a case of restored sensitivity to endocrine therapy in a patient with bone-dominant breast cancer who underwent serial observational FES-PET imaging over the course of several treatments at our center, demonstrating the temporal heterogeneity of regional ER expression. Although loss and restoration of endocrine sensitivity in patients who have undergone prior hormonal and cytotoxic treatments has been reported, this is, to our knowledge, the first time the accompanying changes in ER expression have been documented by molecular imaging.

AB - Changes in estrogen receptor (ER) expression over the course of therapy may affect response to endocrine therapy. However, measuring temporal changes in ER expression requires serial biopsies, which are impractical and poorly tolerated by most patients. Functional ER imaging using 18F-fluoroestradiol (FES)-PET provides a noninvasive measure of regional ER expression and is ideally suited to serial studies. Additionally, lack of measurable FES uptake in metastatic sites of disease predict tumor progression in patients with ER-positive primary tumors treated with endocrine therapy. This report presents a case of restored sensitivity to endocrine therapy in a patient with bone-dominant breast cancer who underwent serial observational FES-PET imaging over the course of several treatments at our center, demonstrating the temporal heterogeneity of regional ER expression. Although loss and restoration of endocrine sensitivity in patients who have undergone prior hormonal and cytotoxic treatments has been reported, this is, to our knowledge, the first time the accompanying changes in ER expression have been documented by molecular imaging.

UR - http://www.scopus.com/inward/record.url?scp=84957680451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957680451&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 144

EP - 147

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 2

ER -